Heme oxygenase-1 (HO-1) is an antioxidant enzyme that can protect cardiomyocytes against oxidative stress. In this study, we investigated whether the heme precursor 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC) could protect cardiomyocytes from H 2O2-induced hypertrophy via modulation of HO-1 expression. HL-1 cells pretreated with/without 5-ALA and SFC were exposed to H 2O2 to induce a cardiomyocyte hypertrophy model. Hypertrophy was evaluated by planar morphometry, 3 H-leucine incorporation, and RT-PCR analysis of hypertrophy-related gene expressions. Reactive oxygen species (ROS) production was assessed by 5/6-chloromethyl-2=,7=-ichlorodihydrofluorescein diacetate acetylester. HO-1 and nuclear factor erythroid 2-related factor 2 (Nrf2) protein expressions were analyzed by Western blot. In our experiments, HL-1 cells were transfected with Nrf2 siRNA or treated with a signal pathway inhibitor. We found several results. 1) ROS production, cell surface area, protein synthesis, and expressions of hypertrophic marker genes, including atrial natriuretic peptide, brain natriuretic peptide, atrial natriuretic factor, and ␤-myosin heavy chain, were decreased in HL-1 cells pretreated with 5-ALA and SFC. 2) 5-ALA and SFC increased HO-1 expression in a dose-and time-dependent manner, associated with upregulation of Nrf2. Notably, Nrf2 siRNA dramatically reduced HO-1 expression in HL-1 cells. 3) ERK1/2, p38, and SAPK/JNK signaling pathways were activated and modulate 5-ALA-and SFCenhanced HO-1 expression. SB203580 (p38 kinase), PD98059 (ERK), or SP600125 (JNK) inhibitors significantly reduced this effect. In conclusion, our data suggest that 5-ALA and SFC protect HL-1 cells from H 2O2-induced cardiac hypertrophy via activation of the MAPK/ Nrf2/HO-1 signaling pathway. 5-aminolevulinic acid; heme oxygenase-1; nuclear factor erythroid 2-related factor 2; cardiomyocyte hypertrophy; mitogen-activated protein kinase OXIDATIVE STRESS OCCURS when excess reactive oxygen species (ROS) cannot be adequately countered by intrinsic antioxidant systems and are accumulated in cells. An increasing amount of evidence suggests that ROS play an important role in triggering cardiac hypertrophic response (19). Several studies have demonstrated that the intrinsic antioxidants vitamin E and superoxide dismutase can ameliorate the hypertrophy via reduction of ROS production (5, 33). In addition, a reductase inhibitor simvastatin can act as an antioxidant and prevent hypertrophy through inhibition of the production of ROS (31). Thioredoxin is a ubiquitous thiol oxidoreductase that could also limit oxidative stress by direct ROS scavenging (36).
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Heme oxygenase-1 (HO-1), a cytoprotective enzyme, can degrade heme to bilirubin, carbon monoxide, and iron and thereby plays a critical role in cardioprotection. Several studies have shown that HO-1 could attenuate prooxidant-or angiotensin II-induced cardiac hypertrophy via inhibition of ROS production (8, 13, 32) . Pretreatment of the cardiomyocytes with heme metabolite bilirubin inhibited the antihypertrophic effects of HO-1 (2). Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription gene demonstrated as responsible for regulating antioxidant and cellular genes primarily in response to oxidative stress (28) . Ample evidence suggests that Nrf2 could upregulate the expression of HO-1 in different cell models through regulation of multiple signal pathways (4, 17, 22) .
Heme (iron protoporphyrin IX) exists as a prosthetic group and is involved in several cellular functions, such as oxygen sensing, cell respiration and metabolism, and cell growth. Heme biosynthesis is a rate-limiting step in cells. The end product heme can block the conversion of glycine to aminolevulinic acid (ALA) through the feedback of heme-biosynthesis pathway (35) . 5-ALA is the metabolic precursor of heme (9, 22) . Interestingly, several recent studies indicate that 5-ALA can modulate the mRNA expression of HO-1 in macrophage cells and HepG2 cells (4, 20) . However, little is known about whether 5-ALA and sodium ferrous citrate (SFC) could protect cardiomyocytes from oxidative stress-induced hypertrophy via modulation of Nrf2 and HO-1 expressions.
MAPKs are a group of serine/threonine protein kinases that are activated under diverse extracellular stimuli and mediate signal transduction from cell surface to the nucleus (7). ERK1/2, p38, and SAPK/JNK pathways have been shown to participate in mediation of the upregulation of antioxidant enzymes and HO-1 expression in response to diverse stimuli (10) . Under oxidative conditions, ERK1/2, p38, and SAPK/JNK can enhance the nuclear translocation of Nrf2 (2) . Whether MAPK signal pathways are involved in 5-ALA-and SFC-elicited effects on cardiomyocytes remains unclear.
The objectives of the present study were to assess the protective effects of 5-ALA and SFC in hydrogen peroxide (H 2 O 2 )-induced cardiomyocyte hypertrophy and examine whether MAPK signal pathways are involved. (20) .
MATERIALS AND METHODS

HL
HL-1 cardiomyocyte hypertrophy induction and analysis. To induce a cardiomyocyte hypertrophy model, HL-1 cells were cultured with CMM supplemented with 0.5% FBS, 2 mM L-glutamine, and penicillin/streptomycin for 48 h. The HL-1 cells were then randomly assigned into three groups: control (not exposed to H 2O2), H2O2 (exposed to 200 M H 2O2 for 48 h) (1), and H2O2-5-ALA ϩ SFC (pretreated with 5-ALA ϩ SFC and then exposed to 200 M H 2O2 for 48 h). For signal pathway analysis, SB203580 (5, 10, or 20 M, p38 inhibitor), PD98059 (25, 50, or 100 M, ERK inhibitor), or SP600125 (12.5, 25, or 50 M, JNK inhibitor) was added according to the manufacturers' instructions.
For ROS production analysis, HL-1 cells were incubated with 5/6-chloromethyl-2=,7=-ichlorodihydrofluorescein diacetate acetylester (CM-H2DCFDA; Invitrogen, Burlington, Ontario, Canada) as previously reported (4) .
For planar morphometry analysis, HL-1 cells were digitally photographed using a digital camera (IX70; Olympus, Tokyo, Japan) at ϫ200 magnification by using a digital camera unit DP70 (Olympus). For each well, HL-1 cells in five random fields were photographed, and cell surface areas were measured by using Adobe Photoshop. A minimum of 100 cells was analyzed for each group. For 3 H-leucine incorporation analysis, 48 h after H2O2 treatment, 1 Ci of 3 H-leucine was added to each well in each group for 6 h. Protein was then collected with 5% trichloroacetic acid precipitation, resuspended in 1 M sodium hydroxide, and analyzed using a liquid scintillation counter (LS 1801; Beckman Coulter, Miami, FL). The radioactivity in each sample was normalized against the protein concentration in the control group.
Transfection of HL-1 cells with Nrf2 siRNA. HL-1 cells were transfected with Nrf2 siRNA (Stealth siRNA MSS207018) by using Lipofectamine RNAiMAX (Life Technologies, Grand Island, NY) according to the manufacturer's instructions. Briefly, HL-1 cells (ϳ60 -80% confluent) were cultured with CMM supplemented with Nrf2 siRNA (8.5 g) and Lipofectamine RNAiMAX (17 l) for 24 or 48 h. Cells were then washed with PBS twice and treated with 5-ALA (1,000 M) and SFC (500 M) for 6 h. After treatment, cells were harvested and used for Western blot analysis. Stealth RNAi siRNA negative control (Life Technologies) was used as a negative control of Nrf2 siRNA.
Quantitative real-time PCR analysis. Total RNAs from HL-1 cells from control, H 2O2, and H2O2-5-ALA ϩ SFC groups were extracted using ISOGEN (Nippon Gene, Tokyo, Japan) following the manufacturer's protocol. RNAs were reverse transcribed to cDNAs by using the PrimeScript TR reagent kit (Takara Bio, Shiga, Japan). The target-specific primers and probes were designed as described previously and synthesized by Biosearch Technologies (Novato, CA) as follows: [atrial natriuretic peptide (ANP): forward primer 5=-GCATTCCAGCTCCTAGGTCA-3=, reverse primer 5=-TTC-CAAATGGTCCAGCAAAT-3=; brain natriuretic peptide (BNP): forward primer 5=-TGGAAACGTCCGCGTTAC-3=, reverse primer 5=-AGGGATGTCTGCTCCACCT-3=; ␤-myosin heavy chain (␤-MHC): forward primer 5=-CTGGCACCGTGGACTACAAC-3=, reverse primer 5=-GCACAAAGTGAGGATAGGGT-3=; atrial natriuretic factor (ANF): forward primer 5=-GAGCACACGGATGAAGCG-3=, reverse primer 5=-AGTGGCAATGCGACCAAG-3=; 18S: forward primer 5=-CAGCCTCAAGATCATCAGCA-3=, reverse primer 5=-TGTGGTCATGAGTCCTTCCA-3=]. Real-time PCR was performed in a 25-l reaction mixture containing 12.5 l 2ϫ Premix ExTaq (Takara Bio), 5 pmol primer, and 6.5 l cDNA obtained as above described. Amplification was conducted on the Applied Biosystems PRISM7700 (ABI Japan, Tokyo, Japan). Quantification was determined by the standard curve and 2Ϫ⌬⌬Ct methods (3) .
Immunofluorescence staining. Cells grown on coverslips were fixed with 4% paraformaldehyde for 10 min, permeabilized, and blocked with 0.5% Triton X-100 with 1% bovine serum albumin in PBS for 1 h at room temperature and then incubated with anti-Nrf2 (1:200; Santa Cruz Biotechnology, Santa Cruz, CA) antibodies at 4°C overnight, followed by incubation with a secondary antibody conjugated to FITC for 1 h at room temperature (37) . Cell nuclei were counterstained with propidium iodide (0.10 g/ml) for 1 min (27) . Images were obtained under a confocal microscope (Olympus).
Western blot analysis. Proteins from HL-1 cells were harvested with RIPA lysis buffer (Wako, Osaka, Japan) containing phosphatase inhibitor cocktail and protease inhibitor cocktail from different groups at indicated time points (25) . Proteins were subjected to electrophoresis and transferred onto PVDF membranes (Bio-Rad, Hercules, CA). The membranes were blocked with 3% skim milk containing 0.1% sodium azide (Wako) for 1 h at room temperature and then incubated with primary antibodies overnight at 4°C. After being washed three times, membranes were probed with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. Blots were developed with an enhanced chemiluminescence system. The Image Quant LAS 4000 (GE Healthcare, Little Chalfont, Buckinghamshire, UK) was used to measure the relative optical density of each specific band obtained. Statistical analysis. Data are expressed as means Ϯ SD. Statistical comparisons were determined by one-way ANOVA with SAS
(fold of con) β-MHC /18S (fold of con) (Fig. 1B) . In addition, protein synthesis of HL-1 cells was significantly decreased compared with that in the H 2 O 2 group (Fig. 1C) . Meanwhile, according to the RT-PCR results, we found that gene expression of hypertrophy-related genes such as ANP, BNP, ANF, and ␤-MHC was decreased in the 5-ALA and SFC group compared with that in the H 2 O 2 group. Similarly, no significant differences of the expression of these genes were observed between control and 5-ALA ϩ SFC groups (Fig. 2) .
5-ALA plus SFC pretreatment upregulated Nrf2 protein expression, associated with increased HO-1 expression in HL-1 cells.
To investigate the potential effects of 5-ALA and/or SFC on expression of Nrf2 and HO-1, we pretreated the HL-1 cells with various concentration combinations of 5-ALA and SFC. We found that 5-ALA and SFC pretreatment increased the expressions of Nrf2 and HO-1 in a dose-and time-dependent manner (Fig. 3) . Our data show that a combination of 1 mM 5-ALA and 500 M SFC can dramatically upregulate Nrf2 expression (Fig. 3A) and HO-1 protein expression (Fig. 3B) , as analyzed by Western blot. Thus we chose a concentration of 1 mM for 5-ALA and 500 M for SFC for further experiments.
To investigate whether pretreatment time would affect 5-ALA and SFC on Nrf2 and HO-1 expression, we divided HL-1 cells into four groups: control (pretreated with 5-ALA ϩ SFC for 0 h), 1 h (pretreated with 5-ALA ϩ SFC for 1 h), 3 h (pretreat with 5-ALA ϩ SFC for 3 h), and 6 h (pretreat with 5-ALA ϩ SFC for 6 h). We found that 5-ALA (1 mM and SFC (500 M) significantly increased Nrf2 expression and HO-1 protein expression in the 6-h group compared with those in control, 1-h, or 3-h groups (Fig. 3, C and D) . 5-ALA plus SFC pretreatment enhanced the expression of Nrf2 in HL-1 cells. As we found that the increased protein expression of HO-1 is associated with the gene expression of Nrf2, we further conducted immunofluorescence experiments by using Nrf2 antibody to assess the location of Nrf2. We found that 5-ALA and SFC pretreatment stimulated the expression and accumulation of Nrf2 mostly in the cytoplasm, whereas there were no HL-1 cells stained with Nrf2 in the control group (Fig. 4A) .
Silencing Nrf2 attenuated HO-1 expression in HL-1 cells pretreated with 5-ALA and SFC. We conducted the loss-offunction experiment to further test the involvement of Nrf2 on the 5-ALA-and SFC-mediated induction of HO-1 expression. As shown in Fig. 4B , the protein expression of Nrf2 and HO-1 was attenuated in HL-1 cells transfected with Nrf2 siRNA for 24 or 48 h. These data confirmed that 5-ALA-and SFC-mediated induction of HO-1 depended on Nrf2 in HL-1 cells.
Nrf2-dependent MAPK signaling pathway was involved in 5-ALA-and SFC-induced HO-1 expression in HL-1 cells.
Previous studies have demonstrated that the MAPK signaling pathway is actively involved in HO-1 expression in macrophages and HepG2 cells (8, 16) . To investigate whether the upstream regulators of Nrf2 such as p38, ERK1/2, and SAPK/ JNK are involved in 5-ALA-and SFC-induced HO-1 expression, we performed Western blot to analyze the expression of these proteins. We found that p38, ERK1/2, and SAPK/JNK were activated in HL-1 cells pretreated with 5-ALA and SFC. This kinesis may be sustainably active for up to 6 h (Fig. 5A) . However, the level of increased HO-1 protein expression was significantly diminished by each pathway-specific inhibitor, SB203580 (p38 inhibitor), PD98059 (ERK inhibitor), or SP600125 (JNK inhibitor) (Fig. 5B) , suggesting the involvement of MAPK (p38, ERK1/2, and SAPK/JNK) pathways in 5-ALA-and SFC-mediated HO-1 expression in HL-1 cells. 
Con
DISCUSSION
In this study, we have shown that 5-ALA and SFC pretreatment protected against H 2 O 2 -induced cardiomyocyte hypertrophy through enhancing HO-1 expression, and the upregulation of HO-1 was modulated by Nrf2 and the activated MAPK signaling pathways.
Oxidative stress plays a critical role in the pathogenesis of cardiac hypertrophy (23, 26, 34) . 5-ALA is endogenous in animals and is the first compound produced in the heme biosynthetic pathway via 5-ALA synthase (11) . In the present study, we investigated whether 5-ALA and SFC pretreatment could rescue ROS-injured cardiomyocytes from hypertrophy. Our results show that 5-ALA combined with SFC decreased ROS production in HL-1 cells compared with that in control or H 2 O 2 groups. We also found that 5-ALA combined with SFC decreased protein synthesis and cellular size, as revealed by 3 H-leucine incorporation and planar morphometry analyses. In addition, the mRNA levels of hypertrophy-related genes such as ANP, BNP, ANF, and ␤-MHC were decreased in 5-ALAand SFC-pretreated HL-1 cells. These findings demonstrate the protective role of 5-ALA and SFC in cardiac hypertrophy. This is the first study showing that 5-ALA combined with SFC exerts its protective effect on HL-1 cells.
We further examined the underlying molecule mechanism of 5-ALA and SFC on protection of cardiomyocytes from hypertrophy. HO-1 is an antioxidant enzyme (6) . Previous studies have shown that HO-1 could play against phenylephrine-, angiotensin II-, and endothelin 1-induced cardiomyocyte hypertrophy (21) . Hence, we assessed the protein expression of HO-1 in HL-1 cells with or without pretreatment with 5-ALA and SFC. Our data show that 5-ALA and SFC pretreatment enhanced HO-1 expression in a dose-and time-dependent manner. We found that a combination of 1,000 M 5-ALA and 500 M SFC exhibited an optimal effect on upregulation of the expression of Nrf2 and HO-1 in HL-1 cells exposed to H 2 O 2 . We also observed that expression of Nrf2 and HO-1 was significantly enhanced in cells pretreated with 5-ALA (1,000 M) and SFC (500 M) for 6 h. However, whether this effective concentration is proper for human study requires further investigation on a human cell line because the bioavailability of 5-ALA has been shown to be different between mice and humans (12, 29) . It is well established that Nrf2 is a master regulator of cellular redox status (30) . Several reports have demonstrated that Nrf2 could positively regulate the induction of some cytoprotective proteins such as HO-1 (17, 28) . In our study, we explored whether 5-ALA and SFC pretreatment-enhanced HO-1 expression is related to the regulation of Nrf2. As expected, we found that the expression level of Nrf2 was dramatically increased in cytosol to nuclear HL-1 cells pretreated with 5-ALA and SFC, associated with the upregulation of HO-1 cells, as we discussed above. To confirm our finding, we silenced Nrf2 by using siRNA. The loss-of-function data show that there was a dramatically decreased expression of HO-1 in HL-1 cells transfected with Nrf2 siRNA. This finding is in agreement with a recent study showing that Nrf2 can positively modulate the expression of HO-1 in macrophages and HepG2 cells (24) .
Numerous studies have shown that MAPKs are a highly conserved family of protein serine/threonine kinases, including p38, ERK, and JNK subgroups (15) . MAPK signaling pathway has been shown to be a central regulatory pathway for Nrf2 activation associated with inducible expression of antioxidant enzymes HO-1 (14, 17) . Little is known, however, about whether the MAPK signaling pathways are involved in the upregulation of HO-1 in HL-1 cells pretreated by 5-ALA and SFC. Hence, we analyzed the effects of 5-ALA and SFC on the MAPK cascades leading to the activation of p38, ERK, and JNK. We found that 5-ALA and SFC induced HO-1 upregulation associated with the phosphorylation of p38, ERK, and JNK. Incubation of the HL-1 cells with specific pathway inhibitors with various concentrations significantly decreases the protein expression of HO-1. These data suggest that MAPK signal pathways are involved in upregulated expression of HO-1 in HL-1 cells pretreated with 5-ALA and SFC.
In conclusion, 5-ALA and SFC effectively upregulated the expression of HO-1 in HL-1 cells exposed to H 2 O 2 via activation of the MAPK/Nrf2 signal pathway. Our results suggested that 5-ALA and SFC may be novel negative regulators of oxidant-induced cardiac hypertrophy.
